Rockland Immunochemicals Acquires antibodies-online GmbH with financing from BroadOak Capital

AVS Bio Acquires ImmunoPrecise Antibodies (Europe) B.V.

August 6, 2025

Biotechnology

AVS Bio, a portfolio company of Arlington Capital Partners, has acquired ImmunoPrecise Antibodies (Europe) B.V., a carve-out from ImmunoPrecise Antibodies Ltd. The acquisition expands AVS Bio's European footprint and adds antibody discovery, recombinant protein expression, and organoid growth factor development capabilities to its biologics services platform.

Merck Acquires OncoImmune

November 23, 2020

Biotechnology

Merck will acquire all outstanding shares of clinical-stage biopharmaceutical OncoImmune for $425 million upfront in cash, with additional sales-based and regulatory milestone payments possible. The deal centers on accelerating development of OncoImmune’s CD24Fc for severe and critical COVID-19; non-CD24Fc assets will be spun out into a new company in which Merck will invest $50 million for a minority stake.

Ligand Pharmaceuticals Acquires Crystal Bioscience

October 4, 2017

Biotechnology

Ligand Pharmaceuticals acquired Crystal Bioscience for $25 million in cash plus up to $10.5 million in milestones and revenue sharing, adding Crystal's chicken-derived HuMab (OmniChicken) antibody discovery platform and an in-house discovery lab. The acquisition (closing announced Oct 4, 2017) brings four fully-funded partnership programs, is expected to be accretive to revenue and earnings, and expands Ligand's OmniAb platform capabilities.

Genmab Acquires ProfoundBio for $1.8 Billion

April 3, 2024

Biotechnology

Genmab A/S will acquire clinical-stage biotech ProfoundBio, Inc. in an all-cash transaction valued at USD 1.8 billion to obtain worldwide rights to ProfoundBio's pipeline of antibody-drug conjugates (ADCs), including rinatabart sesutecan (Rina-S). The deal is intended to broaden and strengthen Genmab's oncology and ADC capabilities and is expected to close in the first half of 2024, subject to customary conditions.

NorthEdge Completes Multi‑Million‑Pound Investment into Antibody Analytics

November 2, 2023

Biotechnology

NorthEdge has completed a multi‑million‑pound growth investment in Antibody Analytics (now trading as RoukenBio), a Scotland‑based pre‑clinical immunology CRO. The capital will fund site expansion, upgraded facilities and job creation as NorthEdge (represented on the board by Liam May) backs CEO Andy Upsall and the leadership team to scale the business internationally.

BroadOak Capital Partners and RCT Invest in Biolog, Inc.

May 12, 2022

Biotechnology

BroadOak Capital Partners and Research Corporation Technologies (RCT) made a growth capital investment in Biolog, Inc., a Hayward, California-based provider of cell-based microbial identification and phenotypic profiling technologies. As part of the recapitalization, Robert Wicke was named CEO and the company will use proceeds to advance its cellular analysis product portfolio and expand commercial adoption across pharmaceutical, academic, biotech and environmental markets.